Community curated by people like you

Human Papillomavirus stories

Nov 5, 2026

FDA grants J&J accelerated approval for head and neck cancer treatment

The FDA granted accelerated approval to Johnson & Johnson's treatment for patients with advanced head and neck cancer whose disease has worsened after prior therapy.

Nov 5, 2026·2 sources

00

Top claims

▪Intravenously infused Rybrevant received its initial FDA approval in 2021 for treating non-small cell lung cancers harboring an EGFR mutation
▪Rybrevant is a bispecific antibody designed to block EGFR and MET, two receptors overexpressed in certain cancers, to overcome single-target treatment resistance
▪For the first nine months of 2026, Johnson & Johnson reported $866 million in global Rybrevant/Lazcluze sales, representing a 67.4% year-over-year increase

Topics

FDA drug approval Cancer & Oncology Accelerated approval pathways Targeted cancer therapy Drug Policy, Pricing & Approval Biologic therapies Clinical trials Advanced drug delivery formulations

Related entities

Non-small cell lung cancer Rybrevant